Key facts
- CuraFi’s last known valuation is $20.4M (Mar 2023).
- It has raised $7.3M; the latest was Early Stage VC in Mar 2025.
- Notable investors include Riverside Ventures, Tau Ventures, Max Ventures, AV8 Ventures, Arvin Grover — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for CuraFi
- ·The full record, as it builds
Funding rounds
No funding rounds for CuraFi are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CuraFi
Developer of an integrated specialty pharmacy and care delivery payment platform designed to improve affordability and access to specialty medications. The company's platform improves outcomes by aligning physicians and payors, permits them to manage patients' costs, lower mediation costs, and provide predictable and sustainable payments on a per-member-per-month basis, enabling healthcare centers to provide access to life-saving medication and deliver cost-effective care.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2022
- Employees
- 13
- Website
- curafi.com/
- Ownership
- Privately Held (backing)
CuraFi doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CuraFi shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CuraFi in its N-PORT filings yet. We sweep new filings monthly.